LON:PRTC - PureTech Health Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 140 +4.00 (+2.94 %)
(As of 07/23/2018 01:31 PM ET)
Previous CloseGBX 136
Today's RangeGBX 135 - GBX 155
52-Week RangeGBX 111.50 - GBX 183.50
Volume1.02 million shs
Average Volume71,917 shs
Market Capitalization£379.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PureTech Health logoPureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Receive PRTC News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolLON:PRTC
CUSIPN/A
Phone+1-617-4822333

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-10,126.32%
Return on Equity-53.32%
Return on Assets-47.28%

Miscellaneous

EmployeesN/A
Outstanding Shares237,430,000
Market Cap£379.89

PureTech Health (LON:PRTC) Frequently Asked Questions

What is PureTech Health's stock symbol?

PureTech Health trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."

What price target have analysts set for PRTC?

5 brokers have issued 1-year price objectives for PureTech Health's shares. Their forecasts range from GBX 245 to GBX 313. On average, they expect PureTech Health's share price to reach GBX 266.25 in the next year. This suggests a possible upside of 90.2% from the stock's current price. View Analyst Ratings for PureTech Health.

What is the consensus analysts' recommendation for PureTech Health?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PureTech Health in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are PureTech Health's key executives?

PureTech Health's management team includes the folowing people:
  • Ms. Daphne Zohar, Founder, CEO & Exec. Director (Age 47)
  • Dr. Bennett M. Shapiro, Co-Founder & Non-Exec. Director (Age 78)
  • Dr. Robert S. Langer Jr., Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 69)
  • Mr. Stephen M. Muniz J.D., COO, Exec. VP of Legal & Operations, Sec. and Exec. Director (Age 48)
  • Dr. Bharatt M. Chowrira, Pres and Chief of Bus. & Strategy (Age 53)

Has PureTech Health been receiving favorable news coverage?

Media headlines about PRTC stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PureTech Health earned a news impact score of 0.15 on Accern's scale. They also assigned news coverage about the company an impact score of 48.83 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of PureTech Health?

Shares of PRTC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is PureTech Health's stock price today?

One share of PRTC stock can currently be purchased for approximately GBX 140.

How big of a company is PureTech Health?

PureTech Health has a market capitalization of £379.89 million.

How can I contact PureTech Health?

PureTech Health's mailing address is 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States. The company can be reached via phone at +1-617-4822333.


MarketBeat Community Rating for PureTech Health (LON PRTC)

Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  341 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about PureTech Health and other stocks. Vote "Outperform" if you believe PRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Featured Article: What are CEFs?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.